Latest Neuroscientific Biopharmaceuticals (Asx:Nsb) News

Page 1 of 1
NeuroScientific Biopharmaceuticals has initiated treatment of its fourth patient under the Special Access Scheme for StemSmart™, progressing towards a Phase 2 trial targeting severe Crohn’s disease.
Ada Torres
Ada Torres
11 Nov 2025
NeuroScientific Biopharmaceuticals has secured regulatory approval for initial patient treatments under its Special Access Program for StemSmart™ in Crohn’s disease, alongside key executive appointments and a manufacturing partnership to support upcoming clinical trials.
Ada Torres
Ada Torres
30 Oct 2025
NeuroScientific Biopharmaceuticals reported a $1.85 million loss for FY25, driven by reduced R&D incentives and increased development costs following its acquisition of StemSmart™ technology. The company is advancing clinical programs, including a Special Access Scheme for Crohn’s disease.
Ada Torres
Ada Torres
28 Aug 2025
NeuroScientific Biopharmaceuticals reports encouraging early clinical results for its StemSmart™ MSC therapy in preventing and treating kidney transplant rejection and injury.
Ada Torres
Ada Torres
27 Aug 2025
NeuroScientific Biopharmaceuticals has appointed Nathan Smith as CEO, leveraging his deep cell therapy expertise to accelerate clinical development and commercialisation of its StemSmart technology.
Ada Torres
Ada Torres
28 July 2025
NeuroScientific Biopharmaceuticals has completed its acquisition of StemSmart technology, reporting promising clinical results in Crohn’s disease and GVHD, alongside a $3.5 million capital raise to fuel next-stage development.
Ada Torres
Ada Torres
23 July 2025
NeuroScientific Biopharmaceuticals has completed its acquisition of StemSmart stem cell technology, setting the stage for a focused clinical push in treating fistulising Crohn’s disease. The company also refreshed its board and raised $7.5 million to support this next phase.
Ada Torres
Ada Torres
27 June 2025
NeuroScientific Biopharmaceuticals reveals compelling clinical evidence supporting its StemSmart MSC therapy for severe steroid-refractory graft versus host disease, advancing its strategic acquisition plans.
Ada Torres
Ada Torres
19 June 2025
NeuroScientific Biopharmaceuticals has initiated critical IND-enabling studies for its glaucoma drug candidate EmtinB, backed by a solid cash position of A$4.5 million as of December 2024. Preliminary melanin binding results are shaping the path toward first-in-human trials.
Victor Sage
Victor Sage
30 Jan 2025